 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...458459460461462463464465466467468...522523» |
- | Jakafi (ruxolitinib) / Incyte
Trial completion date, Trial initiation date, Combination therapy: Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 15, 2018
P1, N=15, Not yet recruiting, Sponsor: University of Chicago
Trial completion date: Sep 2025 --> Sep 2024 | Initiation date: Sep 2018 --> Sep 2019
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment open: SGN35-027: Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma (clinicaltrials.gov) - Oct 15, 2018
P4, N=180, Recruiting, Sponsor: Seattle Genetics, Inc.
Trial completion date: Sep 2025 --> Sep 2024 | Initiation date: Sep 2018 --> Sep 2019 Not yet recruiting --> Recruiting
- | Opdivo (nivolumab) / BMS, Rituxan (rituximab) / Roche
New P1/2 trial, Combination therapy: NCI-2018-01666: Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 15, 2018
P1/2, N=30, Not yet recruiting, Sponsor: Northwestern University
- | doxorubicin hydrochloride / Generic mfg.
New P4 trial: CineDoxo: Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE (clinicaltrials.gov) - Oct 14, 2018
P4, N=10, Not yet recruiting, Sponsor: University Hospital, Strasbourg, France
- | Ninlaro (ixazomib) / Takeda
Trial primary completion date: Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults (clinicaltrials.gov) - Oct 12, 2018
P1, N=28, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2019 --> Oct 2016
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial primary completion date: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas (clinicaltrials.gov) - Oct 11, 2018
P3, N=452, Active, not recruiting, Sponsor: Seattle Genetics, Inc.
Trial primary completion date: Mar 2019 --> Oct 2016 Trial primary completion date: Dec 2018 --> Aug 2018
- | Enrollment closed: PVAB: Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin (clinicaltrials.gov) - Oct 11, 2018
P2, N=90, Active, not recruiting, Sponsor: The Lymphoma Academic Research Organisation
Trial primary completion date: Dec 2018 --> Aug 2018 Recruiting --> Active, not recruiting
- | plinabulin (BPI 2358) / BeyondSpring
Enrollment open: PROTECTIVE-2: Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia (clinicaltrials.gov) - Oct 11, 2018
P2/3, N=237, Recruiting, Sponsor: BeyondSpring Pharmaceuticals Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
Trial completion date, Trial primary completion date: Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer (clinicaltrials.gov) - Oct 10, 2018
P2, N=60, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Recruiting Trial completion date: Sep 2018 --> Mar 2019 | Trial primary completion date: Sep 2018 --> Mar 2019
- | Phase classification: Combination Chemotherapy in Treating Patients With Sarcoma (clinicaltrials.gov) - Oct 10, 2018
P1, N=28, Completed, Sponsor: Mayo Clinic
Trial completion date: Sep 2018 --> Mar 2019 | Trial primary completion date: Sep 2018 --> Mar 2019 Phase classification: P=N/A --> P1
- | bortezomib / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 10, 2018
P2, N=18, Completed, Sponsor: Stanford University
Phase classification: P=N/A --> P1 Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Jul 2017 | Trial primary completion date: Sep 2017 --> Nov 2016
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date: NCI-2015-00960: Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Oct 9, 2018
P2, N=131, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Jul 2017 | Trial primary completion date: Sep 2017 --> Nov 2016 Trial completion date: Jun 2022 --> Jun 2021
- | doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
Clinical, P3 data, Journal: Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. (Pubmed Central) - Oct 6, 2018
Despite international collaboration to test the role of adjuvant chemotherapy in uterine-confined leiomyosarcoma, this study was closed for accrual futility. Although the sample size precludes robust statistical comparison, observed OS and recurrence-free survival data do not show superior outcomes with adjuvant chemotherapy.
- | Rituxan (rituximab) / Roche
Enrollment closed: Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Oct 5, 2018
P2, N=49, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Although the sample size precludes robust statistical comparison, observed OS and recurrence-free survival data do not show superior outcomes with adjuvant chemotherapy. Recruiting --> Active, not recruiting
- | Lartruvo (olaratumab) / Eli Lilly
Enrollment closed, Enrollment change, Trial completion date, Combination therapy, Monotherapy: A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 5, 2018
P1b, N=61, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Completed --> Active, not recruiting | N=40 --> 61 | Trial completion date: Jul 2018 --> Jun 2019
- | Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) / Roche
Trial completion date, Trial primary completion date, Combination therapy: FeDeriCa: A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer (clinicaltrials.gov) - Oct 5, 2018
P3, N=500, Recruiting, Sponsor: Hoffmann-La Roche
Completed --> Active, not recruiting | N=40 --> 61 | Trial completion date: Jul 2018 --> Jun 2019 Trial completion date: Aug 2024 --> Apr 2024 | Trial primary completion date: Mar 2020 --> Nov 2019
- | Mepact (mifamurtide) / Takeda
Enrollment open, Metastases: SARCOME13: Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (clinicaltrials.gov) - Oct 5, 2018
P2, N=126, Recruiting, Sponsor: UNICANCER
Trial completion date: Aug 2024 --> Apr 2024 | Trial primary completion date: Mar 2020 --> Nov 2019 Not yet recruiting --> Recruiting
- | Lartruvo (olaratumab) / Eli Lilly
New P2 trial, Metastases: OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients (clinicaltrials.gov) - Oct 4, 2018
P2, N=60, Not yet recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
- | bortezomib / Generic mfg., thioguanine / Generic mfg.
Trial primary completion date: AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 4, 2018
P3, N=1400, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2022 --> Dec 2023
- | Votrient (pazopanib) / Novartis, BeiGene
Trial suspension, Trial primary completion date, Surgery: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (clinicaltrials.gov) - Oct 4, 2018
P2/3, N=340, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2022 --> Dec 2023 Recruiting --> Suspended | Trial primary completion date: Jun 2019 --> Mar 2020
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed: Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) (clinicaltrials.gov) - Oct 2, 2018
P3, N=1150, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Suspended | Trial primary completion date: Jun 2019 --> Mar 2020 Recruiting --> Active, not recruiting
- ||| Trial completion date: TAC Versus TC for Adjuvant Breast Cancer (clinicaltrials.gov) - Oct 1, 2018
P3, N=1296, Active, not recruiting, Sponsor: US Oncology Research
Recruiting --> Active, not recruiting Trial completion date: May 2017 --> May 2019
- | doxorubicin hydrochloride / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: SPEED: Bridge to Orthotopic Liver Transplantation (OLT) - Surefire Precision vs Endhole Embolization With DEBTACE (clinicaltrials.gov) - Oct 1, 2018
P=N/A, N=11, Terminated, Sponsor: University of Colorado, Denver
Trial completion date: May 2017 --> May 2019 N=50 --> 11 | Trial completion date: Apr 2020 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Sep 2018; Sponsor withdrew funding
- | Rituxan (rituximab) / Roche
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma (clinicaltrials.gov) - Sep 28, 2018
P2, N=58, Terminated, Sponsor: M.D. Anderson Cancer Center
N=50 --> 11 | Trial completion date: Apr 2020 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Sep 2018; Sponsor withdrew funding N=120 --> 58 | Trial completion date: Mar 2020 --> Sep 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2019 --> Sep 2018
- | tamoxifen / Generic mfg.
Clinical, Journal: Rare case of metaplastic breast cancer in a man. (Pubmed Central) - Sep 28, 2018
Two years after treatment, he is currently living with no signs of recurrence. This case will serve as a useful addition to the current literature discussing successful diagnosis, treatment and prognosis of a man with MBC.
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Combination therapy, Metastases: Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer (clinicaltrials.gov) - Sep 27, 2018
P2, N=37, Completed, Sponsor: MolMed S.p.A.
This case will serve as a useful addition to the current literature discussing successful diagnosis, treatment and prognosis of a man with MBC. Active, not recruiting --> Completed
- | doxorubicin hydrochloride / Generic mfg.
Journal: Tumor-targeting and pH-responsive nanoparticles from hyaluronic acid for the enhanced delivery of doxorubicin. (Pubmed Central) - Sep 27, 2018
Furthermore, confocal laser scanning microscopy (CLSM) images and flow cytometric profiles of HeLa cells showed an efficiently cellular uptake due to the receptor-mediated affinity of CD44 for HA with high specificity. These results suggest that this pH dependent drug delivery system based on HA will provide insights into the design of potential prodrugs for the cancer therapy.
- | Halaven (eribulin mesylate) / Eisai
Trial completion: Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer (clinicaltrials.gov) - Sep 26, 2018
P2, N=81, Completed, Sponsor: Eisai Inc.
These results suggest that this pH dependent drug delivery system based on HA will provide insights into the design of potential prodrugs for the cancer therapy. Active, not recruiting --> Completed
- | doxorubicin hydrochloride / Generic mfg.
Journal: KLLN-mediated DNA damage-induced apoptosis is associated with regulation of p53 phosphorylation and acetylation in breast cancer cells. (Pubmed Central) - Sep 26, 2018
After doxorubicin treatment, Thr454-phosphorylation of DBC1, required to inhibit deacetylation of p53 by SIRT1, was decreased and therefore acetylation of p53 was also decreased with KLLN knockdown. Therefore, our observations suggest that KLLN's role in DNA damage-induced apoptosis is likely independent of p53 and is associated with a two-pronged regulation of p53 activation.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Computerized Approach to Creating a Systematic Ontology of Hematology/Oncology Regimens. (Pubmed Central) - Sep 23, 2018
These capabilities may be particularly valuable in the implementation of rapid-learning health systems on the basis of real-world evidence. The derived Web Ontology Language ontology is freely available for noncommercial use through the Creative Commons 4.0 Attribution-NonCommercial-ShareAlike license.
- | Rituxan (rituximab) / Roche
Phase classification, Trial completion date: NCI-2018-01851: Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma (clinicaltrials.gov) - Sep 20, 2018
P1/2, N=110, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
The derived Web Ontology Language ontology is freely available for noncommercial use through the Creative Commons 4.0 Attribution-NonCommercial-ShareAlike license. Phase classification: P1 --> P1/2 | Trial completion date: Apr 2021 --> Apr 2020
- | Lartruvo (olaratumab) / Eli Lilly
Enrollment change, Metastases: A Study of Olaratumab in Japanese Participants With Advanced Cancer (clinicaltrials.gov) - Sep 20, 2018
P1, N=25, Active, not recruiting, Sponsor: Eli Lilly and Company
Phase classification: P1 --> P1/2 | Trial completion date: Apr 2021 --> Apr 2020 N=18 --> 25
- | bortezomib / Generic mfg., melphalan / Generic mfg., thalidomide / Generic mfg.
Trial completion date, Trial primary completion date: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (clinicaltrials.gov) - Sep 19, 2018
P3, N=177, Active, not recruiting, Sponsor: University of Arkansas
N=18 --> 25 Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019
- | Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date: BRCAP-GELTAMO12: Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. (clinicaltrials.gov) - Sep 19, 2018
P2, N=121, Completed, Sponsor: Grupo Espa
Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019 Active, not recruiting --> Completed | Trial primary completion date: Jun 2018 --> Jan 2018
- | aldoxorubicin (INNO-206) / NantWorks
Review, Journal: Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas. (Pubmed Central) - Sep 19, 2018
Specifically, we highlight available data on the pharmacokinetics and efficacy from Phase I, Phase II, and Phase III trials in advanced or metastatic STS. We conclude with considerations for future directions of investigation for this promising antitumor agent.
- | Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche, Biogen
New P1/2 trial, Combination therapy: GO40515: A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 19, 2018
P1/2, N=160, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change, Metastases: Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Sep 18, 2018
P2, N=48, Completed, Sponsor: Sarcoma Alliance for Research through Collaboration
We conclude with considerations for future directions of investigation for this promising antitumor agent. N=74 --> 48
- | Enrollment closed: SINTART2: Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients (clinicaltrials.gov) - Sep 18, 2018
P2, N=27, Active, not recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
N=74 --> 48 Recruiting --> Active, not recruiting
- | Enrollment closed, Surgery: SINTART 1: Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients (clinicaltrials.gov) - Sep 18, 2018
P2, N=41, Active, not recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Biomarker, Trial primary completion date: NEOSarcomics: CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study. (clinicaltrials.gov) - Sep 18, 2018
P=N/A, N=205, Recruiting, Sponsor: Institut Bergoni
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2018 --> Jan 2019
- | Tecentriq (atezolizumab) / Roche
Enrollment open, Trial initiation date: HOVON 151: The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL (clinicaltrials.gov) - Sep 18, 2018
P2, N=114, Recruiting, Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
Trial primary completion date: Jan 2018 --> Jan 2019 Not yet recruiting --> Recruiting | Initiation date: Apr 2018 --> Aug 2018
- | dasatinib / Generic mfg.
Trial completion date, Trial primary completion date: Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. (clinicaltrials.gov) - Sep 17, 2018
P2, N=107, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Apr 2018 --> Aug 2018 Trial completion date: Aug 2018 --> Aug 2020 | Trial primary completion date: Aug 2018 --> Aug 2020
- | Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Surgery: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (clinicaltrials.gov) - Sep 17, 2018
P2/3, N=340, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Aug 2018 --> Aug 2020 | Trial primary completion date: Aug 2018 --> Aug 2020 Trial primary completion date: Dec 2018 --> Jun 2019
- | Bavencio (avelumab) / EMD Serono
New P2 trial: Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (clinicaltrials.gov) - Sep 16, 2018
P2, N=196, Recruiting, Sponsor: Jules Bordet Institute
- | Clinical, Journal: Outpatient Transarterial Chemoembolization of Hepatocellular Carcinoma: Review of a Same-Day Discharge Strategy. (Pubmed Central) - Sep 15, 2018
Same-day discharge after transarterial chemoembolization does not increase the risk of 30-day readmission. Child-Pugh B/C patients, as well as those with ascites or encephalopathy, have the highest risk of readmission.
- | topotecan / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion date, Trial primary completion date: Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer (clinicaltrials.gov) - Sep 14, 2018
P1, N=22, Active, not recruiting, Sponsor: University of Nebraska
Child-Pugh B/C patients, as well as those with ascites or encephalopathy, have the highest risk of readmission. Trial completion date: Dec 2020 --> Jul 2020 | Trial primary completion date: Dec 2018 --> Jul 2019
- | doxorubicin hydrochloride / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Cardiac Fibrosis by CMR in Patients With Cancer (clinicaltrials.gov) - Sep 14, 2018
P=N/A, N=0, Withdrawn, Sponsor: Massachusetts General Hospital
Trial completion date: Dec 2020 --> Jul 2020 | Trial primary completion date: Dec 2018 --> Jul 2019 N=12 --> 0 | Trial completion date: Feb 2019 --> Aug 2018 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2019 --> Aug 2018
- | New P3 trial, Head-to-Head, Metastases: RANDOMET: Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm) (clinicaltrials.gov) - Sep 13, 2018
P3, N=110, Not yet recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial primary completion date: ATLANTIS: Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (clinicaltrials.gov) - Sep 12, 2018
P3, N=613, Active, not recruiting, Sponsor: PharmaMar
N=12 --> 0 | Trial completion date: Feb 2019 --> Aug 2018 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2019 --> Aug 2018 Trial primary completion date: Jun 2019 --> Feb 2020
- | plinabulin (BPI 2358) / BeyondSpring
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: PROTECTIVE-2: Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia (clinicaltrials.gov) - Sep 12, 2018
P2/3, N=237, Active, not recruiting, Sponsor: BeyondSpring Pharmaceuticals Inc.
Trial primary completion date: Jun 2019 --> Feb 2020 Recruiting --> Active, not recruiting | N=180 --> 237 | Trial completion date: Dec 2018 --> Apr 2019 | Trial primary completion date: Jul 2018 --> Oct 2018